Considering Avonex® (interferon beta-1a)?
The EVIDENCE study, a head-to-head trial, compared Rebif with Avonex for an average of 64 weeks. Rebif 44 mcg was given to 339 people 3 times per week just under the skin, at least 48 hours apart. Avonex 30 mcg was given to 338 people once per week into the muscle. • Rebif 44 mcg was proven to work better than Avonex 30 mcg at reducing relapses and brain lesion activity on MRI.* Of the 605 people who completed the head-to-head phase of the EVIDENCE study, 73% of people taking Avonex and 91% of people taking Rebif chose to take Rebif 44 mcg in the extension phase of the study (n = 495), which lasted an average of 8 months. • People who chose to change to Rebif 44 mcg from Avonex 30 mcg during the extended phase of the EVIDENCE study experienced a reduction in both relapses and new or enlarging brain lesions. Results were compared with patients’ last 6 months on Avonex.* • People who chose to stay on Rebif during the extended phase of the EVIDENCE study experienced continued reductions i
